Depressive Symptoms Correlate With Tau Accumulation Rates in Amyloid Positive Adults
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Depression is linked to faster tau buildup in the brain for individuals with Alzheimer's disease (AD) who are amyloid-positive. This suggests depression may indicate AD progression and warrants further research as a modifiable risk factor.
Area Of Science
- Neurodegenerative diseases
- Alzheimer's disease research
- Geriatric psychiatry
Background
- Depression is a common comorbidity in Alzheimer's disease (AD).
- Depressive symptoms in AD are associated with accelerated cognitive decline and increased tau pathology.
- Understanding the relationship between depression and AD biomarkers is crucial for disease management.
Purpose Of The Study
- To investigate the association between depressive symptoms and the rate of tau accumulation in older adults.
- To examine if Geriatric Depression Scale (GDS) scores correlate with tau accumulation in the temporal lobe.
- To explore this relationship within the context of amyloid positivity in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.
Main Methods
- Utilized data from 303 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
- Assessed serial [18F]-flortaucipir tau positron-emission tomography (PET) scans from 2015-2022.
- Correlated Geriatric Depression Scale (GDS) scores with annualized tau accumulation rates in temporal lobe regions, adjusting for covariates.
Main Results
- A positive correlation was found between Geriatric Depression Scale (GDS) scores and annualized tau accumulation rates.
- This association was significant in amyloid-positive participants.
- No significant correlation was observed in amyloid-negative participants.
Conclusions
- Depressive symptoms are associated with accelerated tau accumulation in amyloid-positive individuals with Alzheimer's disease.
- Depression may serve as an indicator of Alzheimer's disease pathology progression.
- Further research into depression as a modifiable risk factor for Alzheimer's disease is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...